How To Know If Cellectar Biosciences Inc (NASDAQ:CLRB) Is Expensive At $3.50.

In last trading session, Cellectar Biosciences Inc (NASDAQ:CLRB) saw 0.46 million shares changing hands with its beta currently measuring 0.92. Company’s recent per share price level of $3.50 trading at -$0.01 or -0.28% at ring of the bell on the day assigns it a market valuation of $43.02M. That closing price of CLRB’s stock is at a discount of -25.14% from its 52-week high price of $4.38 and is indicating a premium of 62.86% from its 52-week low price of $1.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.34 million shares which gives us an average trading volume of 1.39 million if we extend that period to 3-months.

Cellectar Biosciences Inc (NASDAQ:CLRB) trade information

Upright in the red during last session for losing -0.28%, in the last five days CLRB remained trading in the red while hitting it’s week-highest on Monday, 02/05/24 when the stock touched $3.50 price level, adding 5.41% to its value on the day. Cellectar Biosciences Inc’s shares saw a change of 26.35% in year-to-date performance and have moved -6.91% in past 5-day. Cellectar Biosciences Inc (NASDAQ:CLRB) showed a performance of 0.86% in past 30-days. Number of shares sold short was 1.67 million shares which calculate 0.67 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Cellectar Biosciences Inc (CLRB) estimates and forecasts

Statistics highlight that Cellectar Biosciences Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 102.31% of value to its shares in past 6 months, showing an annual growth rate of 25.43% while that of industry is 17.10. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -11.10% in the current quarter and calculating 28.00% increase in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 48.04% during past 5 years.

CLRB Dividends

Cellectar Biosciences Inc is more likely to be releasing its next quarterly report between March 07 and March 11 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Cellectar Biosciences Inc (NASDAQ:CLRB)’s Major holders

Insiders are in possession of 6.61% of company’s total shares while institution are holding 23.56 percent of that, with stock having share float percentage of 25.23%. Investors also watch the number of corporate investors in a company very closely, which is 23.56% institutions for Cellectar Biosciences Inc that are currently holding shares of the company. AIGH Capital Management LLC is the top institutional holder at CLRB for having 0.68 million shares of worth $2.37 million. And as of Sep 29, 2023, it was holding 5.51% of the company’s outstanding shares.

The second largest institutional holder is Worth Venture Partners, Llc, which was holding about 0.28 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 2.27% of outstanding shares, having a total worth of $0.98 million.

On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2023, the former fund manager was holding 99704.0 shares of worth $0.35 million or 0.81% of the total outstanding shares. The later fund manager was in possession of 69393.0 shares on Sep 29, 2023, making its stake of worth around $0.24 million in the company or a holder of 0.56% of company’s stock.

On Key

Related Posts